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Abstract.  We have identified monoclonal antibodies 
that inhibit human cell adhesion to collagen (P1H5), 
fibronectin (P1F8  or P1D6),  and collagen and fibronec- 
tin (P1B5)  that react with a  family of structurally simi- 
lar glycoproteins referred to as extracellular matrix 
receptors (ECMRs) II, VI, and I, respectively. Each 
member of this family contains a unique ¢t subunit, 
recognized by the antibodies, and a  common [~ 
subunit, each of ~140 kD. We show here that ECMR 
VI is identical to the fibronectin receptor (FNR), very 
late antigen (VLA) 5,  and platelet glycoproteins Ic-IIa 
and shall be referred to as FNR.  Monoclonal antibod- 
ies to FNR inhibit lymphocyte, fibroblast, and platelet 
adhesion to fibronectin-coated surfaces. ECMRs I, H, 
and FNR were differentially expressed in platelets, 
resting or activated lymphocytes, and myeloid, epithe- 
lial, endothelial, and fibroblast cell populations,  sug- 
gesting a  functional role for the receptors in vascular 
emigration and selective tissue localization. Tissue 
staining of human fetal skin localized ECMRs I and II 
to the basal epidermis primarily, while monoclonal an- 
tibodies to the FNR stained both the dermis and epi- 
dermis. Experiments carried out to investigate the 
functional roles of these receptors in mediating cell 
adhesion to complex extracellular matrix (ECM) pro- 
duced by cells in culture revealed that complete inhibi- 
tion of cell adhesion to ECM required antibodies to 
both the FNR and ECMR II, the collagen adhesion 
receptor.  These results show that multiple ECMRs 
function in combination to mediate cell adhesion to 
complex EMC templates and predicts that variation in 
ECM composition and ECMR expression may direct 
cell localization to specific tissue domains. 
ECENTLY, we identified a family of cell surface glyco- 
proteins that mediate fibroblast adhesion to specific 
components of the extracellular matrix (ECM) ~ and 
are referred to as extracellular matrix receptors (ECMRs) I 
and II (Wayner and Carter,  1987).  Monoclonal antibody to 
ECMR II (P1H5)  specifically inhibited fibroblast (Wayner 
and Carter, 1987) and nonactivated platelet (Kunicki et al., 
1988)  adhesion  to  collagen,  while  monoclonal  antibody 
against ECMR I (P1B5) inhibited fibroblast adhesion to fibro- 
nectin  (FN),  collagen,  and  laminin  (Wayner and  Carter, 
T. J. Kunicki is an established investigator (83-186)  of the American Heart 
Association. 
1. Abbreviations used in this paper: CTL, cytotoxic T lymphocyte; ECM, 
extracellular matrix; ECMR, extracellular matrix receptor; FN, fibronec- 
tin; FNR, fibronectin receptor; LAK, lymphokine activated killer; PBMC, 
peripheral blood mononuclear cells; VLA, very late antigens. 
1987). Both members of  this ECMR family contained a com- 
mon 13 and a unique a  subunit, each with a molecular mass 
of ~140 kD. The 13 subunit was identified as the 131, subunit 
of the Integrin (Hynes, 1987) family of receptors (Wayner 
and Carter, 1987).  Subsequent studies (Takata et al.,  1988) 
indicated that the functionally defined P1B5 and P1H5 mono- 
clonal antibodies reacted with the a3 and a2 subunits of the 
very late antigens (VLA), respectively. Since the monoclo- 
nal antibodies previously used to describe the VLA 3 and 
VLA 2 antigens (J143 [Fradet et al. 1984] and 12FI [Pischel 
et al.  1987], respectively) had no apparent functional activ- 
ity, it is now possible to describe the VLA 3 and VLA 2 anti- 
gens as ECMRs for collagen and possibly other ligands. 
Despite promiscuity in binding capability, ECMR I was 
remarkably similar to the fibronectin receptor (FNR) described 
by Pytela et al.,  (1985) and others (Damsky et al.,  1985; 
Brown and Juliano, 1985, 1986).  Furthermore, monoclonal 
antibodies to ECMR I partially inhibited cell adhesion to FN 
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nor II monoclonal antibodies reacted with the FNR isolated 
by RGDS peptide elution from FN-Sepharose, we concluded 
that ECMR I  and II represented two new members of the 
family of ECMRs that included the FNR. However, without 
a specific probe for the FNR it was not possible to evaluate 
the cooperative roles of multiple ECMRs in mediating cell 
localization  in  tissue.  For example,  previously described 
polyclonal and  monoclonal antibodies  that  react with the 
Integrin 1~  subunit inhibit cell adhesion to multiple ECM 
components (Horwitz et al., 1985) by reacting with multiple 
ECMRs. Similarly, RGD-containing peptides that inhibit cell 
adhesion to ECM components are also not specific enough 
for evaluating the cooperative role of multiple ECMRs. This 
is due to the functional expression of the RGD sequence in 
many adhesive ECM components, including FN, thrombo- 
spondin, vitronectin, osteopontin, vWF, and tenasin (Ruos- 
lahti and Pierschbacher,  1987). 
In the present studies:  (a) we describe monoclonal anti- 
bodies P1F8 and P1D6 that specifically inhibit the adhesion 
of human cells to FN, but not collagen or laminin.  These 
antibodies  react  with  a  140-kD  surface  receptor,  termed 
ECMR VI; (b) we show that ECMR VI is identical to the 
FNR, to platelet glycoproteins Ic-IIa, and VLA 5, and that 
P1F8 and P1D6  specifically inhibit fibroblast,  lymphocyte, 
and platelet adhesion to fibronectin-coated surfaces; (c) we 
examine the differential expression of the ECMRs on multi- 
ple human cell populations both in culture and in tissue. The 
results  suggest their widespread distribution and possible 
function as mediators of cell adhesion to the ECM in tissue; 
(d) the availability of multiple monoclonal antibodies that in- 
hibit the function of specific ECMRs allowed us to evaluate 
their combined roles in mediating cell adhesion to ECM pro- 
duced by WI-38 human embryonic lung fibroblasts. Our re- 
suits indicate that multiple ECMRs function to mediate cell 
adhesion to ECM and predicts the possible combined action 
of multiple ECM and ECMR components in localizing cells 
to specific tissue domains. 
Materials and Methods 
Materials 
Phenylmethylsulfonyl fluoride  (PMSF),  N-ethylmaleimide,  diisopropyl 
fluorophosphate, 2-mercaptoethanol, BSA,  Triton X-100,  EDTA, protein 
A-Agarose, and V8 protease (from Staphylococcus aureus, strain V8, pro- 
tease type XVII) were purchased from Sigma Chemical Co.  (St. Louis, 
MO). Lactoperoxidase and glucose oxidase were from Calbiochem-Behring 
Corp. (San Diego, CA). Fluorescein-conjugated goat anti-mouse IgG and 
IgM (H and L chains) or rhodamine-conjugated goat anti-rabbit IgG and 
IgM (H and L chains) were obtained from Tago Inc. (Burlingame, CA). Rab- 
bit anti-mouse IgG (H +  L) antiserum was obtained from Cappel Laborato- 
ries (Malvern,  PA).  ~tCr-sodium chromate was from New England Nu- 
clear (Boston, MA).  ~25I was from Amersham Corp.  (Arlington Heights, 
IL). The gly-arg-gly-asp-ser  (GRGDS) peptide was obtained from Peninsula 
Laboratories, Inc. (Belmont, CA). Human recombinant interleukin-2 was 
a generous girl from Dr.  D.  Urdal (Immunex Corp., Seattle, WA). 
Cells and Cell Culture 
Normal diploid human embryonic lung fibroblasts, WI-38 cells, and SV-40 
virus  transformants of WI-38  cells,  WI-38  VA13 cells,  and  a  human 
fibrosarcoma (HT1080)  were obtained from the American Type Culture 
Collection (Rockville, MD).  Primary cultures of human fetal  skin fibro- 
blasts were prepared by collagenase digestion of tissue. Human fetal skin 
was obtained from Dr. Thomas H. Shepard (Central Lab for Human Em- 
bryology,  University of Washington, Seattle, WA).  The human carcinoma 
cell lines: MKN 45 (poorly differentiated gastric adenocarcinoma), MKN 
28 (well differentiated gastric adenocarcinoma), HuTu 80 (carcinoma of the 
duodenum),  MCF-7  (breast adenocarcinoma),  A431 (epidermoid carci- 
noma), and QG-56 (squamous cell carcinoma of the lung) were obtained 
from Dr.  Sen-itiroh Hakomori (Fred Hutchinson Cancer Center, Seattle, 
WA).  Human Tera-2  cells (human embryonal carcinoma) were obtained 
from Dr. Bruce Fenderson (Biomembrane Institute, Seattle, WA).  Fibro- 
blast and carcinoma cell lines were grown as monolayer cultures in RPMI 
1640 supplemented with 10% FBS. OC-1 cells were obtained from sterile 
ascites removed from a patient with metastatic carcinoma of the ovary and 
were used fresh in suspension for flow cytometry. Primary cultures of nor- 
mal human neonatal foreskin keratinocytes were obtained from Dr. Pritin- 
der Kaur at the Fred Hutchinson Cancer Resarch Center. 
Peripheral blood mononuclear cells (PBMC) from normal human donors 
were purified on ficoll/hypaque (d =  1.077) according to a standard protocol 
(Mishell and Shiigi, 1980). Adherent monocytes were obtained by allowing 
unfractionated PBMC to adhere on tissue culture dishes in the presence of 
2% FBS for 30 min at 37°C. The plastic nonadherent peripheral blood lym- 
phocytes were collected and consisted of 80-90%  T  lymphocytes by cell 
surface phenotype analysis (CD2+, CD3+). The adherent cells consisted 
of 80-90 % monocytes by morphological criterion. Granulocytes were puri- 
fied from ficoll/hypaque pellets by ammonium chloride lysis of red blood 
cells and contained >95 % neutrophils and <5 % eosinophils, basophils, and 
lymphocytes. Human lymphokine activated killer (LAK) cells (Grimm et 
al., 1982) were prepared by incubating plastic nonadherent peripheral blood 
lymphocytes at  2  ×  106 cells/ml in Click's medium supplemented with 
10% FBS and 500 U/ml human recombinant interleukin-2 for 7-14 d. The 
monoclonal HLA B7 specific human cytotoxic T lymphocyte (CTL) cell line 
was established using a  standard protocol (Glasebrook and Fitch,  1980; 
Brooks, 1983). CTL and LAK ceils demonstrated the surface phenotype of 
classical cytotoxic T  lymphocytes (CD2+,  CD3+,  CD8+,  CD4-,  Leu 
lib-, OKMI-). All other lymphoid cell lines, Molt 4 (T cell leukemia), 
HL-60 (promonocyte cell line), and BLCL (Epstein Barr virus transformed 
B lymphocyte cell line) were maintained in suspension in RPMI 1640 sup- 
plemented with 10% FBS. Unactivated human platelets were obtained from 
the peripheral blood of normal donors as described (Kunicki et al., 1985). 
Antibodies 
Rabbit polyclonal antibodies prepared against the FN receptor as described 
by Pytela et al. (1985) were a generous girl from Dr. M. D. Pierschbacher 
(La Jolla Cancer Research Federation, La Jolla, CA). Monoclonal antibody 
AIA5 against the common Integrin (Hynes, 1987) 13~ subunit of the VLA 
family of receptors (Hemler, 1988) was obtained from Dr.  Martin Hemler 
(Dana-Farber Cancer Inst., Boston, MA). Monoclonal anti-ECMR I and 
II (Wayner and Carter, 1987) and their relation to the VLAs (Takada et al., 
1988) have been described. Rabbit polyclonal antibodies to type VI collagen 
and flbronectin were prepared and characterized as previously described 
(Carter, 1982).  Rabbit polyclonal antibodies to laminin were prepared and 
found to be specific for laminin by immunoblotting and solid phase radioim- 
munoassay. 
Monoclonal anti-ECMR VI (anti-FNR) was produced by the methods of 
Oi and Herzenberg (1980) and Taggart and Samloff (1983),  as described in 
detail  (Wayner  and Carter,  1987).  Immune spleens from RBF/Dn mice 
(Jackson Labs, Bar Harbor, ME) immunized with 100 p,l of packed LAK 
cells were removed and fused with NS-1/FOX-NY myeloma cells. Viable 
heterokaryons were selected in RPMI  1640  supplemented with adenine/ 
aminopterin/thymidine, AAT, (Taggart and Samloff, 1983).  Heterokaryons 
producing antibody directed to the fibronectin receptor were screened by 
specific inhibition of cell adhesion to FN. Selected hybrids were cloned by 
limiting dilution with thioglycolate-induced, irradiated BALB/c peritoneal 
macrophages or thymocytes as feeder cells. 
Inhibition of Cell Adhesion 
Antibodies that would alter cell adhesion to either or both FN or collagen 
Types I and III were selected as previously described (Wayner and Carter, 
1987).  Briefly,  48-well  virgin  styrene plates  were  coated  with  pepsin- 
generated type I and III collagen or human plasma FN (5 ~tg/ml). The plates 
were blocked with PBS (137 mM NaCl, 2.7 mM KCI, 0.7 mM CaCI2,  10 
mM Na2HPO4,  1.5 mM K2HPO4) supplemented with l0 mg/ml heat dena- 
tured BSA. HT1080 cells were labeled with Na25tCrO4 (50 p.Ci/ml for 2-4 h), 
washed, and 5  x  104 cells per well were incubated with the hybridoma cul- 
ture supernatants  (1:2 dilution in PBS supplemented with 1 mg/ml heat dena- 
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temperature. The cells were allowed to adhere to the protein-coated surfaces 
in  the presence of the hybridoma supernatants for  15-30  min at 37°C. 
Nonadherent cells were removed by washing with PBS, and the adherent 
cells were dissolved in SDS/NaOH, and bound 51Cr-cpm were quantitated 
in a gamma counter. 
Platelet adhesion to FN and collagen-coated surfaces was as previously 
described (Kunicki et al.,  1988). 
Preparation of  Adhesive Proteins 
FN: human plasma FN was purified from human plasma by affinity chroma- 
tography on gelatin-Sepharose according to the method of Engvall and 
Ruoslahti (1977).  Pepsinized  collagen types I and III: all collagens were iso- 
lated from fresh human placenta after digestion with pepsin as described 
by Miller and Rhodes (1982).  Laminin: mouse laminin was isolated from 
Englebreth-Holmswarm sarcoma grown in BALB/c mice as described by 
Timpl et al.  (1979). 
Preparation of WI-38 ECM 
WI-38 cells were grown to confluence in 24-weU tissue culture plates in the 
presence of 10 ~tg/ml ascorbate. The adherent cells and ECM were extracted 
basically as previously described to prepare an adherent ECM composed 
primarily of FN and type VI collagen,  previously referred to as GP140 
(Carter,  1982,  1984):  (a)  empigen BB zwitterionic detergent to remove 
membrane, and cytoplasmic components; (b) 2 M urea in 1 M NaCI to solu- 
bilize cytoskeletal and nuclear components; (c) digestion with DNase I (10 
ttg enzyme/ml PBS for 30 rain at 37°C) to remove residual DNA present 
in the ECM layer. The stable ECM was then used in adhesion and inhibition 
studies as described in Fig. 9. 
Immune Precipitation and Sequential Immune 
Precipitation 
HT1080,  LAK ceils, and platelets were surface labeled with radioactive 
iodine using the lactoperoxidase/glucose oxidase method (Hynes,  1973), 
followed by extraction with 1% vol/vol Triton X-100 detergent in 25  mM 
Tris-HCl buffer, pH 7.5, (Triton/Tris) containing 1 mM diisopropyl fluoro- 
phosphate, or 1 mM PMSF plus 2 mM N-ethylmaleimide as protease inhib- 
itors. Immune precipitation and sequential immune precipitation were per- 
formed as previously described (Wayner and Carter,  1987). 
V8 Protease Peptide Analysis 
Peptide analysis came after the basic procedure of Cleveland et al. (1977) 
with modifications as previously described (Wayner and Carter,  1987). 
Isolation of  RGDS-eluted FNR: Reactivity of  FNR with 
Class I, H, and VI MonoclonaI Antibodies 
FN receptor was isolated from octlyglucoside  extracts basically as described 
by Pytela et al. (1985) and as follows. Labeled HTI080 cells were extracted 
in 100 mM octylglucoside detergent in PBS at 4°C containing 1 mM PMSF 
as a protease inhibitor. The octylglucoside extracts were chromatographed 
on insoluble FN at 4°C and washed with octylglucoside (25 mM) in PBS. 
A  140-kD  bound receptor was specifically eluted with the peptide gly-arg- 
gly-asp-ser (I mg/ml). FN-Sepharose was prepared as previously described 
(Wayner and Carter,  1987). 
PAGE 
Polyacrylamide slab gels containing SDS (SDS-PAGE gels) were prepared 
after the basic stacking gel system of Laemmli (1970) and as previously de- 
scribed (Wayner and Carter, 1987).  Prestained protein standards for relative 
molecular mass estimation were obtained from Bethesda Research Labora- 
tories (Gaithersburg,  MD)  and  were as  follows:  lysozyme,  14,300  kD; 
I~-lactoglobulin,  18,400  kD;  ct-chymotrypsin,  25,700  kD;  ovalbumin, 
43,000  kD; BSA, 68,000 kD; phosphorylase B, 9%400 kD; and myosin (H 
chain) 200,000  kD. 
Two-dimensional SDS gels that were run under reducing and nonreduc- 
ing conditions were performed as described (Kunicki et al.,  1988). 
Figure I. Isolation of ECMR VI- 
specific  monoclonal  antibodies. 
Effect of anti-ECMR I, II, and VI 
monoclonal antibodies  on  adhe- 
sion of HT1080 cells to fibronec- 
tin- or collagen-coated surfaces. 
S~Cr-labeled  HT1080  cells  were 
incubated in the presence of hy- 
bridoma culture supernatants anti- 
ECMR  I  (PIB5),  anti-ECMR 
II  (P1H5),  and  anti-ECMR  VI 
(P1F8),  and allowed to adhere to 
fibronectin- (F) or type I collagen- 
(l) coated plastic surfaces. After 
nonadherent cells were removed, 
adherent  cells  were  solubilized 
and radioactivity quantitated in a 
gamma  counter.  Results  are  ex- 
pressed  as  a  percent  of control 
(myeloma  culture  supernatant) 
adhesion (mean  of three experi- 
ments  +  standard deviation). 
Fluorescence Analysis of  Receptor Expression 
Expression of ECMR classes I, II, and VI on cells in suspension was ana- 
lyzed by flow cytometry on a FACS II cell sorter (Becton Dickinson & Co., 
Sunnyvale, CA). Expression of ECMRs on adherent cells was determined 
by  inununofluorescence microscopy  as  described  (Carter  and  Wayner, 
1988). 
7Issue Staining 
The distribution of  ECMRs I, II, and VI in tissue was determined by fluores- 
cence microscopy of cryostat sections. Cryostat sections (6 kt) were pre- 
pared from human fetal skin, and lung or adult skin and tonsil samples em- 
bedded in OCT medium after snap freezing in isopentane/liquid nitrogen. 
All sections were fixed in 4% paraformaldehyde in PBS before incubation 
in primary antibodies and secondary fluorescent antibodies (Carter and 
Wayner,  1988).  The samples were examined with a Zeiss fluorescence mi- 
croscope using a 40x  oil immersion objective and photographed with Ko- 
dak T-Max film shot at ASA 800.  In control experiments, no fluorescence 
of rhodamine was detected using the fluorescein filters or vice versa. 
Results 
Isolation of  Monoclonal Antibodies that Specifically 
Inhibit Cell Attachment to FN 
Monoclonal antibodies that would inhibit cell adhesion to 
FN were obtained by screening hybridoma culture superna- 
tants for the specific inhibition of fibroblast adhesion to FN- 
coated surfaces. The antibodies that were obtained using this 
protocol, P1F8 and P1D6, reacted with a cell surface receptor 
referred to as ECMR VI and specifically inhibited HT1080 
cell adhesion to FN but not collagen (Fig.  1) or laminin- 
coated  surfaces  (data  not  shown).  Specific  inhibition  of 
HTI080 cell adhesion with the anti-ECMR II (P1H5)  and 
anti-ECMR VI (P1F8) monoclonal antibodies was observed 
on collagen or FN-coated surfaces, respectively (Fig.  1). As 
previously reported (Wayner and Carter, 1987), anti-ECMR 
I (P1B5) monoclonal antibody partially inhibited fibroblast 
attachment to both FN and collagen (Fig.  1). 
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HT1080 FNR by elution with 
RGDS-containing peptide from 
FN-Sepharose  and  immune 
precipitation of purified FNR 
with anti-ECMR VI monoclo- 
nal antibody. Surface-labeled 
HT1080 cells  were  extracted 
with octylglucoside detergent 
(100 mM) in PBS at 4°C. The 
octylglucoside  extracts  were 
chromatographed on FN-Seph- 
arose  at 4°C.  The FNR was 
eluted  with  the  peptide  gly- 
arg-gly-asp-ser  (1 mg/ml), 
and immune precipitated with 
SP2 culture supematant,  anti- 
ECMR I (P1B5), II (PIH5), or 
VI (PIF8) monoclonal antibod- 
ies,  or  polyclonal  antibodies 
specific for the FNR (ct-FNR). 
Figure 2. The effect of 2-mercaptoethanol on the migration of the 
¢t and 13 subunits of ECMRs I, II, and VI. HT1080 cells were sur- 
face labeled  with  radioactive  iodine,  then  extracted  with  Triton 
X-100 detergent. Aliquots of  the extracts were then immune precipi- 
tated  with  SP2  culture  supernatant  or anti-ECMR  I  (P1B5), II 
(P1H5), and VI (P1F8) monoclonal antibodies. The immune precip- 
itates were run on 7% SDS-PAGE gels in the presence (+2-ME) 
or absence (-2-ME) of 2-mercaptoethanol and visualized by auto- 
radiography. Migration of the ct and 13 subunits of the receptors in 
the absence of reducing agent is indicated. 
Biochemical Characteristics of  ECMR VI and 
Comparison with ECMRs I and H 
The P1F8  (Fig. 2) or P1D6 monoclonal antibodies both im- 
mune precipitated  a  single cell  surface protein containing 
two noncovalently linked subunits of 147 and 125 kD, termed 
ct and 13, respectively, from Triton X-100 detergent extracts 
of  ~25I surface-labeled  HT1080  cells  when  run  on  SDS- 
PAGE gels in the absence of 2-mercaptoethanol (Fig. 2, see 
-2-ME  column).  In  the  presence  of 2-ME,  ECMR  VI 
migrated as a single band of ,~135-140 kD (Fig. 2, see +2- 
ME column).  HT1080 ECMR VI appeared to be indistin- 
guishable  from ECMR  I  by  single  dimension  SDS-PAGE 
analysis under both reducing and nonreducing  conditions. 
However, ECMR VI was easily distinguishable from ECMR 
II due  to  the  characteristic  migration  of ECMR  II under 
reducing conditions (Fig. 2,  +2-ME) as resolvable tx and 13 
subunits. 
In a series of control experiments (results not shown) using 
previously described techniques (Wayner and Carter, 1987), 
we have characterized ECMR VI in relation to ECMRs I and 
II as follows. (a) Metabolic pulse-chase studies revealed that 
ECMR VI was not a precursor to any other ECMR and sug- 
gested that the functionally defined monoclonal antibodies, 
P1F8 and P1D6, recognized epitopes on the ¢t or ct-13 subunit 
combinations.  (b)  Sequential  immune precipitation of the 
ECMR I, II, and VI antigens with the appropriate antibodies 
from Triton X-100 detergent extracts of 12~I-labeled HT1080 
cells indicated that neither antibody class recognized antigen 
from the other ECMR classes. However, sequential immune 
precipitation  with  P1F8  quantitatively  precipitated  all  the 
P1D6 antigen present in the extracts, confirming the inhibi- 
tion of cell adhesion results (Fig.  1) that indicated that the 
P1F8  and P1D6 monoclonal antibodies were reacting with 
epitopes present on the same receptor. (c) Peptide mapping 
of the ct subunits of ECMRs I and II produced two distinct 
peptide maps (Wayner and Carter, 1987). Similarly, the pep- 
tide map of the ¢t subunit of ECMR VI was also distinct from 
either  ECMR  I  or  II.  The  peptide  maps  of the  HT1080 
ECMR I, II, and V113 subunits were virtually identical, sug- 
gesting a high degree of amino acid sequence homology and 
clearly  identifying  all  three  receptors  as  members of the 
same ECMR family. In addition, a polyclonal antibody that 
reacts with the 13 subunit of the FNR and a monoclonal anti- 
body, A1A5  that reacts with the Integrin 13t  subunit of the 
VLA family of receptors, both reacted with the 13  subunit 
from all three ECMRs, confirming that the 13 subunits of the 
ECMRs were identical to the 131 subunit of the Integrin su- 
per family of receptors. 
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from K562 cells: ECMR VI is identical to VLA 5. K562 cells were 
surface  labeled  with  1251 and  extracted  with Triton X-100 deter- 
gent. Hemler et al. (1987) has previously published that K562 cells 
express  primarily VLA 5.  Aliquots of labeled extract were sub- 
jected to three cycles of immune precipitation as follows. (A, cycle 1) 
Monoclonal antibody A1A5 was used to precipitate all VLA anti- 
gen containing the common [l~ subunit that  is recognized by the 
A1A5 monoclonal antibody. (cycle 2) The extract was reprecipitated 
with A1A5 to ensure that all VLA antigen was quantitatively re- 
moved. (cycle 3) The VLA-free extract was then immune precipi- 
tated with anti-FNR (P1F8) monoclonal antibodies. (B) The experi- 
ment was also performed in the reverse direction preclearing  first 
with  P1F8 then  with AIA5 to examine whether  monoclonal anti- 
FNR could preclear VLA 5. The antigens brought down in the three 
immune  precipitation  steps  were  analyzed  on  SDS-PAGE gels 
(7.5 %) in the absence of  2-mercaptoethanol followed by autoradiog- 
raphy. 
ECMR VI Is Identical to the FNR, VLA 5, and Platelet 
Glycoprotein lc-lla 
The  relationship  of ECMR  VI  to  the  FNR  described  by 
Pytela et al.  (1985) was examined by immune precipitation 
of affinity-purified and RGDS-eluted FNR (Fig. 3). FNR was 
purified by affinity chromatography of octylglucoside deter- 
gent extracts of 125I surface-labeled HTI080 cells on FN- 
Sepharose. The bound FNR was specifically eluted with the 
GRGDS peptide but not the control peptide, Tuftsin. Mono- 
clonal antibodies prepared against the  ECMR VI immune 
precipitated  the  purified  FNR  (Fig.  3).  Affinity-purified 
FNR also reacted with rabbit polyclonal antibodies prepared 
against the FNR (Pytela et al.,  1985).  This polyclonal anti- 
body preparation precleared ECMR VI antigen,  and cross 
reacted with ECMR VI antigen affinity purified with mono- 
clonal antibody (data not shown).  Neither ECMR I  nor II 
specific monoclonal antibodies  reacted with the  GRGDS- 
eluted FNR (Fig.  3).  These data show that the ECMR VI, 
recognized by the monoclonal antibodies PIF8 and P1D6, is 
identical  to  the  FNR  and  will  therefore be referred to  as 
FNR. 
Takada et al.  (1987) have recently suggested that VLA 5 
is identical to the FNR and is the major VLA expressed in 
K562 ceils.  However, no monoclonal antibody specific for 
the ct subunit of VLA 5 has been described. As seen in Fig. 
4,  P1F8  monoclonal  antibody  quantitatively  immune pre- 
cipitated all the antigen detected by the common 131 subunit- 
specific monoclonal antibody, A1A5, from K562 cells. Both 
P1F8  and P1D6  also completely abrogated K562 cell adhe- 
sion to FN-coated surfaces (results not shown).  Therefore, 
P1F8 and P1D6 clearly react with the VLA 5 antigen and im- 
portantly, completely inhibit K562 cell adhesion to the FN 
ligand. 
Piotrowicz et al. (1988) have recently reported that adhe- 
sion of nonactivated platelets to fibronectin is mediated by 
platelet glycoprotein Ic-IIa. As seen in Fig.  5,  monoclonal 
antibodies P1F8 and P1H5 specifically inhibit platelet adhe- 
sion to fibronectin and collagen, respectively. In contrast to 
results obtained with HTI080 cells, platelet adhesion to FN 
was only partially inhibitable with P1F8. This was in contrast 
to the virtual quantitative nature of the inhibition of platelet 
adhesion to collagen with P1H5 monoclonal antibody. Con- 
ceivably, platelet adhesion to FN may be mediated by more 
than one receptor, only one of which is recognized and in- 
hibited by the P1F8  monoclonal antibody. 
The antigen immune precipitated with the P1F8 antibody 
from t2SI-labeled  platelet extracts was identified as platelet 
glycoproteins Ic and IIa by two-dimensional gel analysis and 
corresponded to the ct and 13 subunits of ECMR VI (FNR), 
respectively (Fig.  6). 
Expression of  ECMRs L II, and FNR on Multiple 
Human Cell Populations 
Analysis of the expression of ECMRs I, II, and FNR on a 
wide variety of human cell populations revealed the univer- 
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Figure 5. Inhibition of platelet 
adhesion  to FN and collagen 
with  P1F8 and  P1H5 mono- 
clonal antibodies,  respective- 
ly.  The effect of monoclonal 
IgG on the adhesion  of 5~Cr- 
labeled platelets to microtiter 
trays  coated  with  fibronec- 
tin (FN)  or type III collagen 
(COL III) was assessed.  AP1 
is an IgG1 murine monoclonal 
antibody  specific  for human 
platelet glycoprotein Ib (Okita 
et al.,  1985). The number of 
platelets adherent to wells coat- 
ed  with  BSA  was  routinely 
<1% of that observed in fibro- 
nectin-coated wells, e, P1F8; 
*, P1H5; ,I., API. 
Wayner et al. ECM Receptor Function and Distribution  in Tissue  1885 Figure 6  Identification of the ¢t and 13 subunits of ECMR VI in platelets as platelet glycoprotein Ic and IIa, respectively. Radioiodinated 
antigens precipitated by P1F8 were mixed with 100 I.tg of nonlabeled platelet protein and subjected to electrophoresis under nonreducing 
(right to left) and then reducing (top to bottom) conditions. Gel stained with silver stain (Silver). The positions of known nonlabeled platelet 
proteins are indicated. (AUTO)  Autoradiograph of gel containing the P1F8 antigen. The positions of radioiodinated proteins that comigrate 
with glycoproteins Ic and IIa are indicated. The migration of IIb and IIIa are also indicated as loops. 
sal expression of these receptors (Table I). What is also im- 
mediately apparent  from  these  data  is  that  different cell 
populations express different quantifies of receptors. Periph- 
eral blood mononuclear cells, platelets, and fibroblasts were 
positive for FNR, while epithelial cells expressed little FNR. 
Alternatively,  epithelial  cells  were positive for ECMR  I, 
while expression of this receptor on mesodermally derived 
cells was restricted primarily to activated lymphocytes (CTL 
and LAK), monocytes, or transformed fibroblasts. Umbilical 
vein endothelial cells, resting small lymphocytes, and plate- 
lets were highly positive for the collagen receptor, ECMR II, 
and expressed little or no ECMR I. As we have previously 
reported expression of ECMR I by cytotoxic T lymphocytes 
requires activation with specific antigen (CTL) or interleu- 
kin-2 (LAK). This is in agreement with our previous finding 
that activated CD8+  T lymphocytes adhere to collagen and 
laminin-coated surfaces (Wayner and Carter,  1987;  Wayner 
and Carter, manuscript submitted for publication). 
Expression of the ECMRs in Human Fetal Skin 
We expected that localization of the ECMRs in tissue would 
correspond to regions that contained the appropriate ECM 
ligand.  As  seen in Fig.  7,  type VI collagen and FN were 
localized throughout the dermis of human fetal skin.  Anti- 
bodies specific for types I or VI collagen and fibronectin did 
not stain epidermis. In contrast, laminin was localized to the 
basement membrane zone and did not extend into the dermis 
except in association with hair follicles as in the field shown 
(Fig.  7) or in glandular epithelium,  not shown.  The P1B5 
monoclonal antibody to the promiscuous ECMR I localized 
to the basal cells of the epidermis that lie in contact with 
laminin located in the basement membrane zone. In contrast, 
ECMR II (P1HS),  the collagen specific receptor, localized 
throughout the epidermis but more intensely in  the more 
differentiated cells than the basal cells that are in contact with 
the basement membrane. FNR (P1F8), in contrast to ECMRs 
I and II, had a much wider distribution and was detected in 
abundance in both the dermis and epidermis. We observed 
similar patterns for the expression of ECMRs I, II, and FNR 
in epithelial and stromal cell populations in various human 
tissue including adult skin, tonsil, fetal lung, and intestine. 
Collagen-binding Site on ECMR H Is Blocked 
in the Dermis 
Interestingly,  antibody  to  the  ECMR  II  (P1H5)  collagen 
receptor failed to localize in the collagen-rich dermis (Fig. 
7).  This was  even more surprising  since we routinely de- 
tected ECMRs I, II, and FNR on fibroblasts derived from 
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Fluorescence intensity:~ 
Cells  I (PIB5)  II (PIHS)  VI (P1FS) 
Lymphocytes 
Nonadherent  peripheral blood lymphocytes  -(*)  + + +(*)  +(*) 
B lymphocyte (EBV transformed)  -  -  + 
Molt 4 (T cell leukaemia)  -(*)  -(*)  + +(*) 
JU KAT (T cell leukaemia)  -(*)  + +(*)  +(*) 
Cytotoxic T lymphocyte (CTL)  +(*)  + + +(*)  + + +(*) 
Lymphokine  activated killer (LAK)  + +(*)  + + +(*)  + + +(*) 
Fibroblasts 
Primary fetal skin fibroblasts  +  + +  + 
WI-38 (embryonic  lung)  +(*)  + +(*)  +(*) 
WI-38 VA13 (SV-40 transformed)  + + +(*)  + + + +(*)  + +(*) 
HT-1080  (fibrosarcoma)  + + +(*)  + + + +(*)  + +(*) 
Epithelial  cells (carcinomas) 
Primary keratinocytes  + +  + +  +/- 
MKN 28 (gastric, adeno)  + +  + +  +/- 
MKN 45  (gastric, adeno)  + +  + +  +/- 
QG 56 (lung, squamous)  +/-(*)  + + +(*)  -(*) 
A431 (epidermoid)  + + +  +  +/- 
MCF-7 (breast,  adeno)  + + +  +  +/- 
Hutu-80  (duodenum)  +  +  +/- 
Tera-2 (teratocarcinoma)  +  -  - 
OC-1 (ovarian)  + + +  -  +/- 
Others 
Adherent monocytes  +  + + +  + + 
Granulocytes  -  +/-  - 
HL-60  (promonocyte)  -  -  + 
K562 (erythroleukemia)  -  -  + + 
Endothelial  cells (umbilical)  +/-  + + +  + 
Platelets  (unactivated)  - (*)  + + + (*)  + (*) 
~: Fluorescence  intensity was determined  by flow cytometry  on nonadherent cells  and by fluorescence  microscopy  on adherent cells. The asterik indicates  those 
results that have been  confirmed  by immune precipitation  with the indicated  antibodies  and SDS-PAGE  gel analysis.  The minus sign indicates  no detectable  fluores- 
cence or band formation  on SDS-PAGE  gels. 
primary cultures of the same skin used for tissue staining 
(Table I). In control experiments other membrane glycopro- 
teins,  including the ECMR  III 90-kD  intrinsic membrane 
glycoprotein (Wayner and Carter,  1987; Carter and Wayner, 
1988) or the FNR, were readily detected in the dermis and 
epidermis with monoclonal antibodies (Fig. 7).  Thus,  our 
failure to detect staining in the dermis with ECMR II (P1H5) 
monoclonal antibodies was not due to inaccessibility of the 
plasma membranes of the stromal cells. The P1H5 monoclo- 
nal antibody used in the above studies was originally selected 
for its ability to inhibit cell adhesion to collagen and there- 
fore  may  react  with  an  epitope  in  or  near  the  collagen- 
binding site on the ECMR Ilct subunit (Figs.  1 and 2).  Be- 
cause the dermis is rich in its content of collagen types that 
have been shown to mediate fibroblast adhesion via ECMR 
II, we reasoned that the epitope recognized by P1H5 on cell~_ 
in the dermis might be blocked with ligand. Alternatively, 
the  epitope recognized by  the  P1H5  monoclonal  antibody 
may be cryptic or conformation dependent. To test these pos- 
sibilities, we  rescreened  our  battery  of hybridomas  for  a 
monoclonal  antibody that  reacted  with  an  epitope on  the 
ECMR IIa subunit that was distal from the collagen-binding 
site and would therefore not inhibit cell adhesion. Monoclo- 
nal antibody P4B4  was  selected on the basis of the above 
criteria and was characterized as follows (results not shown). 
(a) P4B4 precleared ECMR II, but not ECMR I, from de- 
tergent extracts  of HT1080  cells.  (b)  pH-induced  subunit 
dissociation experiments  indicated  that,  like  P1H5,  P4B4 
reacted with the a  subunit of ECMR II. (c) In contrast to the 
P1H5 monoclonal antibody, P4B4 had no effect on cell adhe- 
sion to collagen indicating that it reacted with an epitope on 
the IIQ subunit that was distal from the collagen binding site 
(Fig. 8). (d) Both the P1H5 and P4B4 monoclonal antibodies 
were of the IgG2b subclass and therefore had similar access 
capabilities in the tissue. 
Using P4B4, ECMR II was found to distribute in both the 
dermis and epidermis in contrast to the results obtained with 
P1H5  (Fig.  7).  Two  conclusions  can  be made  from  these 
data: (a) the ECMR II codistributes in dermis with intersti- 
tial collagen as well as in epidermis, and (b) virtually all of 
the epitope recognized by the P1H5 monoclonal antibody is 
blocked or cryptic in the dermis, possibly because it is bound 
to collagen. In contrast,  in the epidermis,  where collagen 
deposition is minimal (Fig. 7),  the epitopes recognized by 
both the P1H5  and P4B4  antibodies are both detected. 
Role of  Multiple ECMRs in Mediating Cell Adhesion to 
a Complex ECM Containing FN and ~:pe VI Collagen 
The availability of monoclonal antibodies to ECMRs I, II, 
and FNR that selectively inhibit the function of these recep- 
Wayner et al. ECM Receptor Function and Distribution in Tissue  1887 Figure 7. Localization of ECMRs I, II, and FNR (ECMR VI) in human fetal skin sections by immunofluorescence microscopy. Cryostat 
sections of human fetal skin were incubated with the indicated mouse monoclonal antibodies to ECMRs I, II, and VI. Where indicated, 
rabbit polyclonal antibodies were used to localize type VI collagen (COL VI), fibronectin (FN), and laminin (LAM). Bound antibodies 
were detected with rhodamine-conjugated goat anti-rabbit IgG and fluorescein-conjugated goat anti-mouse IgG. In the section marked 
PHASE, the tissue layers corresponding to epidermis, basement membrane zone (BMZ), and dermis are indicated. PHASE, LAM, and 
II (P1H5): same field. COL VI, and I (P1B5): same field. FN and VI (P1D6): different fields. Monoclonal antibodies PIH5 and P4B4 both 
react with the a  subunits of ECMR II, the collagen receptor.  P4B4 does not inhibit cell adhesion to collagen, while P1H5 does.  P41M 
stains both the dermis and epidermis and PIH5 stains only the epidermis. Bar, 50 gM. 
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Figure  & Inhibition  of HT- 
1080 cell adhesion to collagen 
and FN using monoclonal an- 
tibodies  P4B4  and  P1H5 di- 
rected to different epitopes  of 
ECMR  II.  Surfaces  coated 
with collagen (type I, top) and 
fibronectin  (bottom) were in- 
cubated with 5tCr-labeled HT- 
1080 cells  in the presence of 
serial  twofold dilutions  of the 
indicated monoclonal antibod- 
ies in culture medium. PID6, 
anti-ECMR  VI.  P4B4, anti- 
ECMR IIa. PIH5, anti-ECMR 
Ilct.  P4C9, anti-CD18  (LFA, 
1~3  subunit).  Anti-CD18  is  a 
negative  control since  the I}3 
subunit  is  not  expressed  on 
HT1080 cells. 
20  40  60  80 
ANTIBODY  (pg/ml) 
Figure  9.  The  function  of 
ECMRs II and VI in mediat- 
ing WI-38 VA13 cell adhesion 
to WI-38 ECM.  WI-38 cells 
were grown to confluence in 
24-well culture plates then ex- 
tracted to prepare  confluent, 
cell-free  layers  of  ECM  as 
described  in  Materials  and 
Methods. This ECM has been 
previously characterized  and 
contains  primarily  polymer- 
ic FN and type VI collagen. 
51Cr-Labeled  WI-38  VA13 
cells were added to the ECM 
layers  in the presence of the 
indicated purified monoclonal 
antibodies  incubated  for  60 
min,  then  nonadherent  cells 
were removed  by washing  and the adherent cells  dissolved and 
counted in a gamma counter.  Where indicated,  equal quantities  of 
P1H5 and P1D6 were added together to obtain the indicated  final 
concentration of antibody,  e, CONT; m, P1H5;  *, P1D6; and +, 
P1H5 +  P1D6. 
tors allows us to evaluate their individual or combined roles 
in cell adhesion to complex ECM. The effect of monoclonal 
antibodies P1H5 and P1F8 on adhesion of WI-38 VA13 cells 
to WI-38 ECM is shown in Fig. 9. WI-38 ECM is composed 
primarily  of polymeric  fibronectin  and  type  VI  collagen 
(Carter,  1982; 1984). Each antibody alone only partially in- 
hibits cell adhesion to ECM even at saturating levels.  How- 
ever, P1F8 and P1H5 in combination completely inhibited the 
WI-38 VA13 cell adhesion to WI-38 ECM. These data sug- 
gest that ECMR II and FNR function together in mediating 
adhesion to complex ECM composed of multiple  ligands. 
Discussion 
A Model for the Role of  Multiple ECMRs in Mediating 
Cell Adhesion to the ECM 
A  summary  of  our  conclusions  concerning  the  role  of 
ECMRs I, II, and FNR (ECMR VI) in mediating cell adhe- 
sion to a complex ECM are presented in Fig. 10. What is im- 
mediately  evident  from this  model  is  that  two  classes  of 
receptors exist: those like ECMR II and FNR that specifical- 
ly interact with collagen and fibronectin,  respectively,  and 
those that are promiscuous, like ECMR I, that can interact 
with multiple  ECM components.  We have previously sug- 
gested that the extracellular disulfide-dependent assembly of 
type VI collagen (Carter,  1982) is dependent on cell surface 
contact with the ECM (Carter,  1984).  It is conceivable that 
ECMRs like II and FNR that are involved in cell adhesion 
might also be involved in assembly or polymerization of col- 
lagen and  FN in the ECM  (Carter,  1982,  1984).  We have 
reported that other membrane components also interact with 
collagen,  such  as  the  90-kD  phosphorylated,  transmem- 
brane glycoprotein, termed ECMR III (Carter and Wayner, 
1988; Wayner and Carter,  1987). These components have no 
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Figure 10. Model showing fibroblast adhesion to a 
complex ECM: interaction  of ECMRs I, II, and 
FNR (ECMR VI) with their ECM ligands,  FN, 
and type VI collagen.  Polymeric FN and type VI 
collagen interact with each other and both induce 
cell adhesion  (Carter,  1982;  1984).  FN and type 
VI collagen  specifically  interact  with  the  FNR 
(ECMR VI) and ECMR II, respectively,  to medi- 
ate cell adhesion to the ECM. In addition, both FN 
and type VI collagen interact with the promiscuous 
ECMR I.  ECMR III, a 90-kD transmembrane, 
phosphorylated,  glycoprotein interacts  with  the 
cytoskeleton  and  binds  to  collagen  but  has  no 
defined role in cell adhesion to the ECM (Carter 
and Wayner, 1988).  ECMR III is homologous to 
lymphoid homing receptors  (GaUatin et al., 1986) 
and this intercellular  adhesion may be modulated 
by interactions with the ECM (Carter, Wayner, and 
Gallatin,  unpublished  data).  ECMR IV, a periph- 
eral membrane protein, binds to collagen but also 
has no observed role in cell adhesion to the ECM. 
Wayner et al. ECM Receptor Function and Distribution in Tissue  1889 Table II. Cell Substratum Adhesion Mediated by Extracellular Matrix Receptors (ECMRs) Containing Unique a and 
Common Integrin* [3t Subunits 
a  Subunit  Identifying 
ECM  MW¢  monoclonal  VLA  Related 
ECMR§  ligand  (a-13t)  antibodies§  nomenclaturell  receptors 
-  --  a0  =  160  (CSAT,  JG22)  -  Avian Integrin  1¶ 
-  -  ct~  =  200  (TS  2/7,  SR84)  VLA-1  - 
II  Collagen Types  ctc  =  150  PIH5,  (PIH6,  VLA-2  la/Ilallll 
I-VI  P4B4,  12FI) 
I  Fn,  Lam,  Col  a3  =  150  PIB5,  0143)  VLA-3  Avian Integrin 2 
(Promiscuous?) 
-  -  ct4  =  140  (B-5G10,  HP2/1)  VLA-4  - 
VI  Fn  ~tF  =  150  P1F8, P1D6  VLA-5  FNR**,  Ic/IIa¶1 
-  -  ct6  =  150  (GoH3)  VLA-6  Ic  (?)*~ 
*The  I~  subunit of the Integrin family (Hynes,  1987). 
~: tt Subunit designation based on the ligand, or the subscript used by the original discoverer. Relative molecular weight (MW) estimation under nonreducing con- 
ditions. 
§ Underlined monoclonal antibodies react with the ct subunits or a-13 complexes and inhibit cell adhesion to the indicated ECM ligand. Antibodies in parenthesis 
either do not inhibit activity or are of unknown inhibitory activity. 
II VLA of M.  E.  Hemler (1988) and references therein. The relation of ECMRs to VLAs is described in Takata et al. (1988). 
¶ Buck and Horwitz (1987) and references therein. 
** Pytela et al. (1985). 
¢¢ Hemler et al. (1988) and Sonnenberg et al. (1987). 
§§ Wayner and Carter (1987). 
IIII Kunicki et al. (1988). 
¶¶ Piotrowicz et al.  (1988). 
defined role in cell adhesion to the ECM.  However, the re- 
cent observation that ECMR III is homologous to the lym- 
phoid cell homing receptor (Carter, Wayner, and Gallatin, 
unpublished data) that mediates lymphoid cell interactions 
with high endothelium (Gallatin et al.,  1986) suggests that 
ECMR III may be involved in intercellular adhesion. 
Relation of  ECMRs I, H, and VI (FNR  ) to Receptors 
Described by Others 
As described by Hynes (1987), the Integrin super family con- 
tains a number of families of receptors. Each member of a 
particular  family expresses a  unique a  and a  common 13 
subunit,  termed 13r[33. The relationship of ECMRs  I,  II, 
and VI (FNR) to other receptors is summarized in Table II. 
Human ECMRs I, II, and VI, described here, all share the 
common Integrin 13~ subunit. We have shown that the func- 
tionally defined ECMRs I and II are homologous to the VLA 
3 (monoclonal antibody J143) and VLA 2 (monoclonal anti- 
body  12F1) differentiation antigens  (Takada et al.,  1988). 
Fradet et al. (1984) have also examined the tissue distribution 
of antigens  recognized by  the  J143  monoclonal antibody 
(VLA 3/ECMR I). Our findings, in general, do agree with 
their results. However, the differential staining results we ob- 
tained with monoclonal antibodies P4B4 and P1H5 to ECMR 
II  (Fig.  7)  suggest  that  interactions  of the  ECMRs  with 
ligands can dramatically affect the observed tissue distribu- 
tion  results.  Alternatively,  monoclonal  antibodies  to  the 
same antigen that recognize distinct epitopes may also affect 
tissue distribution results. 
ECMR VI is homologous to the prototype FNR (Pytela et 
al.,  1985)  and  to  the  recently described VLA  5  antigen 
(Takada et al.,  1987). In the present study we have shown 
that platelet glycoprotein Ic-IIa, involved in the adhesion of 
nonactivated platelets  to FN  (Piotrowicz et al.,  1988),  is 
identical to the fibroblast FNR. Furthermore, nonactivated 
platelet adhesion, like fibroblast and lymphoid adhesion to 
FN, can be inhibited with the P1F8 and P1D6 monoclonal an- 
tibodies. In recent work (Kunicki et al.,  1988), we have de- 
termined that the a  and 13 subunits of the collagen receptor, 
ECMR II (P1H5), correspond to platelet glycoproteins Ia and 
IIa, respectively. 
In Table II, we have used the ECMR nomenclature (Way- 
ner and Carter, 1987) when referring to these receptors be- 
cause they were identified as components involved in inter- 
acting with ECM components. The VLA terminology does 
not reflect the relationship of the receptors to the ECM nor 
even to the differentiation state of cells,  since as we have 
shown here and as pointed out by Hemler, the VLAs are often 
not very late appearing antigens (Hemler, 1988). Similarly, 
the nomenclature used for platelet membrane glycoproteins 
does not reflect the function of the receptors. As suggested 
by Buck and Horowitz (1987), the a  subunit of the ECMR 
II has been designated Ctc on the basis of its affinity for col- 
lagen (Table II). 
Function and Expression of  Multiple ECMRs in 
Mediating Cell Distribution in Tissue 
ECMRs were differentially expressed by various cell popula- 
tions  (Table I  and Fig.  7).  In general,  epithelial cells ex- 
pressed elevated levels of ECMRs I and II while circulating 
mononuclear cells  and  platelets  expressed relatively high 
levels of the ECMR II and VI. Characteristically, expression 
of ECMR I was present in only monocytes and activated or 
transformed cell populations. Interestingly, only a subpopu- 
lation of PBMC and platelets expressed the FNR. Cell adhe- 
sion to a complex WI-38 ECM, composed primarily of FN 
and type VI collagen, was mediated by at least two receptors, 
ECMR II and FNR. Conceivably, ECMR I may also play a 
role  in  this  adhesion process  since  monoclonal antibody 
P1B5 against ECMR I,  also partially inhibited (30%) the 
adhesion of WI-38 VA13 cells to the WI-38 ECM. It is clear 
from these data that multiple  receptors contribute to cell 
The Journal of Cell Biology, Volume  107,  1988  1890 adhesion  to  complex  WI-38  ECM.  One  interpretation  of 
these results suggests that a cell expressing different ECMRs 
can adhere to one or more different ligands in complex ECM 
in an additive manner.  In this interpretation,  each ligand- 
receptor  complex  would  function  independently.  Alterna- 
tively,  different  ligand-receptor  complexes  may  function 
cooperatively,  with  each  complex  altering,  (positively  or 
negatively) the function of other ligand-receptor complexes. 
The availability  of multiple monoclonal antibodies that in- 
hibit the adhesive function of unique ECMRs will be useful 
in  further  evaluating  these  possible  mechanisms  and  the 
function of these receptors in mediating morphogenic and 
cell  infiltration  processes  in  tissue.  We  propose  that  the 
differential expression of various ECMRs for multiple ECM 
components (Table I) combined with the cooperative func- 
tion of multiple ECMRs may provide a template  for localiz- 
ing cells to specific tissue domains  such as the dermis or 
epidermis of skin. 
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